{
  "abstract": "Background Patients with non-cystic fibrosis bronchiectasis (NCFBE) often have pulmonary exacerbations (PEx), which are linked to high disease burden. This study explored the association of PEx with morbidity in the UK using primary care data.Methods Patients with NCFBE aged ≥12 years were from THIN ® UK, a longitudinal database of electronic health record extracts recorded by primary care physicians. PEx were defined as GP visits with codes for PEx, haemoptysis, lower respiratory tract infection (LRTI), or antibiotic prescription with either bronchiectasis or ≥1 LRTI symptom. Baseline (previous 12 months, ie, 2018) characteristics and association of PEx with morbidity at follow-up (2019–2022) were assessed.Results Of 12,106 patients included, 15.5% had ≥2 PEx and 84.5% <2 PEx during baseline. Patients with ≥2 baseline PEx (vs with <2 PEx) were more likely to have asthma and COPD and to have received antibiotics and inhaled corticosteroids during baseline ( table 1). Around 70% of patients with ≥2 PEx during baseline had another PEx in year 1 of follow-up vs around 30% with <2 PEx. After adjusting for covariates, having ≥2 PEx during baseline was the strongest predictor of PEx during follow-up (hazard ratio 2.6, 95% CI 2.4–2.8).Abstract S41 Table 1Baseline characteristics, comorbidities, and treatment patterns for patients with NCFBE Baseline characteristics Patients with ≥2 PEx (n=1,881) Patients with <2 PEx (n=10,225) P-value Age, mean (SD) years 70.5 (12.4) 69.4 (13.9) <0.001 Female, n (%) 1,149 (61.1) 5,818 (56.9) 0.001 Comorbidities, n (%) Chronic obstructive pulmonary disease (COPD) 1,121 (59.6) 3,739 (36.6) <0.001 Asthma 1,118 (59.4) 4,288 (41.9) <0.001 Symptoms, n (%) Chronic bronchitis 1,058 (56.2) 3,518 (34.4) <0.001 Lower respiratory tract infection 1,193 (63.4) 1,245 (12.2) <0.001 Treatment, n (%) Any antibiotics 1,866 (99.2) 6,742 (65.9) <0.001 Long-term antibiotics (≥28 days) 448 (23.8) 1,452 (14.2) <0.001 Inhaled corticosteroids 1,260 (67.0) 3,940 (38.5) <0.001 PEx, pulmonary exacerbations; COPD, chronic obstructive pulmonary disease; NCFBE, non-cystic fibrosis bronchiectasisConclusion In UK patients with NCFBE, PEx were associated with higher rates of comorbid asthma and COPD, treatment burden and risk of further PEx, demonstrating the importance of exacerbation reduction and management.",
  "authors": [
    {
      "affiliations": [
        "Imperial College and Royal Brompton Hospital, London, UK"
      ],
      "name": "M Loebinger"
    },
    {
      "affiliations": [
        "Imperial College and Royal Brompton Hospital, London, UK"
      ],
      "name": "J Quint"
    },
    {
      "affiliations": [
        "Insmed Incorporated, Bridgewater, USA"
      ],
      "name": "D Gor"
    },
    {
      "affiliations": [
        "Insmed Incorporated, Bridgewater, USA"
      ],
      "name": "J Feliciano"
    },
    {
      "affiliations": [
        "Cegedim Health Data, Boulogne, France"
      ],
      "name": "I Ghout"
    },
    {
      "affiliations": [
        "Cegedim Health Data, Boulogne, France"
      ],
      "name": "D Acosta-Mena"
    },
    {
      "affiliations": [
        "Cegedim Health Data, Boulogne, France"
      ],
      "name": "A Callet"
    },
    {
      "affiliations": [
        "Cegedim Health Data, Boulogne, France"
      ],
      "name": "C Renaudat"
    }
  ],
  "title": "S41 Morbidity in patients with NCFBE and exacerbations in the THIN UK database",
  "uid": "766d218b-6052-5df7-ad75-bdf123b2c3a0"
}